Symbiotec

Indore, India Founded: 2002 • Age: 24 yrs Listed Acquired By Rosewood Private Intvestments
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
Request Access
Report Incorrect Data
Page last updated

About Symbiotec

Symbiotec is a publicly listed company based in Indore (India) founded in 2002, and was acquired by Rosewood Private Intvestments in December 2018. Non-sterile steroid hormone-based APIs and intermediates are manufactured. Symbiotec has raised $61.01 million across 4 funding rounds from investors including Actis, Franklin Templeton and British International Investment. The company has 1,822 employees. Symbiotec was last valued at $32.19 million in March 2013. Its Indian entity Symbiotec Pharmalab Limited reported revenue of ₹872 Cr. Symbiotec offers products and services including Cortico-Steroid API, Steroid-Hormone API, and Intermediates. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Laurus Labs, Jubilant Pharma and SeQuent; 1 of its 3 listed competitors has raised funding.

Company details

Symbiotec was established in 2002 in Indore, India, as a manufacturer in the pharmaceutical sector. Non-sterile APIs and intermediates derived from steroid hormones are produced, targeting therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, pediatrics, anti-infectives, and dermatology. Regulatory-compliant solutions are offered, alongside operations in research and quality control laboratories.

  • Headquarters Indore, India
  • Employees 1,822
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website symbiotec.in
  • Social LinkedIn X
  • Acquired by Rosewood Private Intvestments (Dec 2018)
  • Legal Name Symbiotec Pharmalab Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹10,267 Cr

    SYMBIOTEC · NSE

  • Share Price
    ₹1,554.70

    -2.70% today

  • Revenue
    ₹869 Cr

    FY 2025-26 · +15.7% YoY

  • EBITDA
    ₹230 Cr

    Margin 26.4%

  • Net Profit
    ₹115 Cr

    FY 2025-26 · +18.9% YoY

  • P/E (TTM)
    71.8x

    P/B 7.2x

  • ROE
    11.2%

    ROCE 12.2%

  • Debt / Equity
    0.48

    Interest cover 14.8x

  • Total Equity Funding
    $61.01M (USD)

    in 4 rounds

  • Latest Funding Round
    $48M (USD), Series C

    Oct 2013

  • Investors
    Actis

    & 8 more

  • Employee Count
    1,822
  • Acquired by
    Rosewood Private Intvestments

    (Dec 2018)

Products & Services of Symbiotec

Symbiotec offers a comprehensive portfolio of products and services, including Cortico-Steroid API, Steroid-Hormone API, and Intermediates.

Cortico-Steroid API
Pharmaceutical API

Active ingredients for corticosteroids in therapies like pain management

Steroid-Hormone API
Pharmaceutical API

APIs for steroid hormones used in dermatology and pediatrics

Intermediates
Chemical Components

Raw materials for API synthesis in pharmaceutical applications

Funding Insights of Symbiotec

Symbiotec has successfully raised a total of $61.01M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $48 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $61.01M
  • Total Rounds 4
  • Last Round Series C — $48M
  • First Round $3.72M

    (Aug 2007)

  • Investors Count 6

All 4 funding rounds of Symbiotec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2013$48MSeries C–Actis
British International Investment
Mar 2013$73,480Angel Round$32.19MR S Shapeti
–
Sep 2011$9.22MSeries A$40.96MFranklin Templeton Investments
–
Aug 2007$3.72MSeries A$•••••Rakesh Jhunjhunwala, Soyumm Marketing
–
Valuation history
DateValuationStage
Mar 2013$32.19M••••••••
Sep 2011$40.96M••••••••
Aug 2007$•••••••••••••
Premium access

Full valuation and stage history of Symbiotec

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $32.19M (Mar 2013). 9 investors in total: 7 institutional and 2 angel.

Investors in Symbiotec

Symbiotec has secured backing from 9 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Actis, Franklin Templeton and British International Investment.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Actis
Sustainable infrastructure projects are invested in for essential services.
1987act.isLondon, United Kingdom
British International Investment
Government agency focused on small and medium-sized businesses
1948bii.co.ukLondon, United Kingdom
Soyumm Marketing
Investments in multiple sectors are managed by Soyumm Marketing.
Mumbai, India
Motilal Oswal Alternates
Motilal Oswal Alternates is engaged in alternative investment management.
motilaloswalalt.comMumbai, India
InvAscent
Private equity firm focused on life sciences investments in India.
2005invascent.com
Franklin Templeton
Diversified investment management services are offered globally by the firm.
1947franklintempleton.comNew York, United States

R S Shapeti

unknown_0221ad53933947a98

Rakesh Jhunjhunwala

unknown_05f1298de59c44aa8
Rosewood Private Investments
Rosewood Private Investments is engaged in private equity investments.
rosewoodpi.comDallas, United States
Premium access

Investor details for Symbiotec

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Symbiotec Pharmalab Limited (Symbiotec)

Symbiotec Pharmalab Limited is the primary company behind Symbiotec. The boards of the 4 registered companies of Symbiotec currently have 11 directors; the longest-serving is Anil Satwani, appointed in 2002. 29 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Anil Satwani
DIN 00041531
Managing Director20 Sep 200224 yrs 1 moSymbiotec Pharmalab Limited, Spl Lifescience India Private Limited, Knovea Pharmaceutical Private Limited
Kashish Satwani
DIN 00041501
Director27 Oct 20188 yrsSpl Lifescience India Private Limited
Rohit Brijmohan Mantri
DIN 07435803
Nominee Director06 Dec 20187 yrs 11 moSymbiotec Pharmalab Limited, Knovea Pharmaceutical Private Limited
Sushil Satwani
DIN 00041575
Designated Partner11 Mar 20233 yrs 8 moTdv Commercials Llp
Kanak Satwani
DIN 10067972
Designated Partner11 Mar 20233 yrs 8 moTdv Commercials Llp
Nitesh Chimnani
DIN 10067971
Designated Partner11 Mar 20233 yrs 8 moTdv Commercials Llp
Buggana Hariharnath
DIN 00695002
Nominee Director16 Sep 20242 yrs 1 moKnovea Pharmaceutical Private Limited
Sunita Kishnani
DIN 06924681
Director27 Nov 202511 moSymbiotec Pharmalab Limited
Pratik Patel
DIN 00780920
Director16 Dec 202510 moSymbiotec Pharmalab Limited
Pramod Kasat
DIN 00819790
Director21 Jul 20263 moSymbiotec Pharmalab Limited
Dhananjay Narendra Mungale
DIN 00007563
Nominee Director06 Aug 20263 moSymbiotec Pharmalab Limited

People of Symbiotec

17 people are tracked at Symbiotec (6 in leadership, 11 in team); the tracked headcount is 1,822.

NameRoleGroup
Nikhil Maru
General ManagerLeadership
Anil Satwani
Managing DirectorLeadership
Jitendra Sharma
Senior General Manager R&dLeadership
Dr D. S. Pandey
Head Corporate QualityLeadership
Nishikant Ghadge
Head - Technical (r&d And Manufacturing)Leadership
Ramana K.
Head Of Research And DevelopmentLeadership
Sukhman Kundi
Regulatory Affairs OfficerTeam
Anand Patel
ManagerTeam
Anil Ramnani
Agm-quality ControlTeam
Sandeep Tiwari
QC ManagerTeam
Sunil K Pandey
Senior GM Quality (sqh)Team
Ashish Sharma
Sr. Manager PPICTeam
Rishi Wagadre
Quality Control Laboratory ManagerTeam
Chitra Saraf
Sr. Scientist In R&d DQATeam
Abhishek Bhardwaj
Deputy ManagerTeam
Jitendra K. Patel
Deputy ManagerTeam
Jaydeep Kalawat
Senior ExecutiveTeam
Premium access

Complete people profiles for Symbiotec

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Symbiotec

Symbiotec is a publicly listed company on the NSE with ticker symbol SYMBIOTEC in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date01 Sep 2026
  • Listed onNSE: SYMBIOTEC
  • Listed entitySymbiotec Pharmalab Limited
  • Exchange sectorHealth technology
  • ISININE899I01028
  • Share price₹1,254.90 (+6.98% on the day) · 2026-10-14
  • Market capitalisation₹7,538 Cr
  • Volume (last session)1,452,150

Financials of Symbiotec

Exchange-reported figures of Symbiotec Pharmalab Limited, the listed company behind Symbiotec (NSE: SYMBIOTEC).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹869 Cr
+15.6% YoY
EBITDA
₹230 Cr
+13.4% YoY
Profit After Tax
₹115 Cr
+18.9% YoY
Net Worth
₹1,150 Cr
+41.1% YoY
Total Assets
₹1,568 Cr
+14.1% YoY
Total Debt
₹391 Cr
-28.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue869752716567682633
Revenue growth+15.7%+4.9%+26.4%-16.9%+7.7%-
EBITDA23020317269.53131195
EBITDA margin+26.4%+27.0%+24.0%+12.3%+19.3%+30.8%
Profit before tax15314713239.33105173
Net profit11596.9710023.4577.53123
Net profit margin+13.3%+12.9%+14.0%+4.1%+11.4%+19.5%
EPS (₹)17.5217.7091.4921.4870.89112.73
Balance sheet
Total assets1,5681,374976848670574
Net worth1,150815715622599521
Total debt39154424721864.6647.42
Cash & bank10.1326.477.565.7110.6948.67
Net working capital279309209278301244
Cash flow
Cash from operations17547.2618869.2417.71174
Cash from investing(227)(307)(206)(220)(31.64)(96.35)
Cash from financing35.9927821.8514615.14(79.28)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue280218245225196203
Revenue growth (YoY)+43.2%+7.4%----
Other income0.110.340.160.150.162.64
EBITDA91.5145.2062.0958.5250.2957.96
EBITDA margin+32.7%+20.7%+25.3%+26.0%+25.7%+28.5%
Depreciation21.8721.8219.7512.4310.5910.51
Interest5.706.187.266.416.395.28
Profit before tax64.0517.5435.2439.8333.4744.81
Tax12.323.477.716.5914.2614.90
Net profit51.7314.0727.5333.2419.2129.91
EPS (₹)8.202.244.760.003.435.34
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue845757674564634623
Revenue growth+11.7%+12.3%+19.5%-11.1%+1.8%-
EBITDA18021914315.52105202
EBITDA margin+21.2%+28.9%+21.2%+2.8%+16.6%+32.5%
Profit before tax173196118(7.78)82.77183
Net profit15614688.9356.9961.72136
Net profit margin+18.5%+19.3%+13.2%+10.1%+9.7%+21.8%
EPS (₹)20.03133.3581.33(20.72)56.45123.96
Balance sheet
Total assets-1,219825787765687
Net worth-911761673695633
Total debt-29351.7210763.5947.42
Cash & bank-22.596.272.836.3241.14
Net working capital-371250278306276
Cash flow
Cash from operations-83.2914793.3523.62158
Cash from investing-(292)(80.80)(132)(33.94)(78.99)
Cash from financing-225(62.98)36.5314.73(79.04)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue220211213226202204
Revenue growth (YoY)+9.0%+3.2%----
Other income20.2319.5518.6814.5312.0511.47
Total expenses160152217165141142
EBITDA59.9859.24(3.87)60.5160.5162.34
EBITDA margin+27.3%+28.1%-1.8%+26.8%+30.0%+30.5%
Depreciation10.0310.1511.319.389.389.30
Interest4.975.626.455.906.345.11
Profit before tax65.2163.02(2.95)59.7656.8459.40
Tax16.6716.0112.7315.3414.2614.90

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 09 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue280218245225196203
Revenue growth (YoY)+43.2%+7.4%----
Other income0.110.340.160.150.162.64
EBITDA91.5145.2062.0958.5250.2957.96
EBITDA margin+32.7%+20.7%+25.3%+26.0%+25.7%+28.5%
Depreciation21.8721.8219.7512.4310.5910.51
Interest5.706.187.266.416.395.28
Profit before tax64.0517.5435.2439.8333.4744.81
Tax12.323.477.716.5914.2614.90
Net profit51.7314.0727.5333.2419.2129.91
EPS (₹)8.202.244.760.003.435.34
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue869752716567682633
Revenue growth+15.7%+4.9%+26.4%-16.9%+7.7%-
Other income3.114.437.096.463.007.03
Total expenses639549544497550438
Employee cost15412210494.0883.6474.67
EBITDA23020317269.53131195
EBITDA margin+26.4%+27.0%+24.0%+12.3%+19.3%+30.8%
Depreciation53.2843.1038.8228.5225.8322.47
Interest26.1416.917.968.143.146.79
Profit before tax15314713239.33105173
Tax43.4650.1930.9314.7828.1848.38
Net profit11596.9710023.4577.53123
Net profit margin+13.3%+12.9%+14.0%+4.1%+11.4%+19.5%
EPS (₹)17.5217.7091.4921.4870.89112.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital12.5510.9410.9410.9410.9410.94
Reserves & surplus1,137804704611588510
Shareholders' funds (net worth)1,150815715622599521
Minority interest(0.14)(0.19)(0.21)(0.09)(0.11)0.04
Secured loans38854124721864.6647.42
Unsecured loans3.083.520.000.000.000.00
Total debt39154424721864.6647.42
Total liabilities1,5681,374976848670574
Assets
Gross block1,401668642454407363
Net block1,120438448299280261
Capital work in progress64.4856820818239.6827.58
Investments4.481.453.514.825.415.36
Inventories237261336244246226
Sundry debtors198176126112144118
Cash & bank balances10.1326.477.565.7110.6948.67
Loans & advances40.9429.2839.1938.7425.6130.66
Total current assets486493508400425423
Total current liabilities207184299122125179
Net working capital279309209278301244
Total assets1,5681,374976848670574
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash26.397.504.559.167.969.25
Net cash from operating activities17547.2618869.2417.71174
Net cash from investing activities(227)(307)(206)(220)(31.64)(96.35)
Net cash from financing activities35.9927821.8514615.14(79.28)
Net change in cash(16.35)18.902.94(4.61)1.21(1.30)
Closing cash10.1326.477.565.7110.6948.67
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+15.7%+4.9%+26.4%-16.9%+7.7%-
EBITDA growth+13.4%+17.7%+147.5%-47.1%-32.5%-
PBT growth+4.3%+11.1%+236.5%-62.7%-38.9%+9997.0%
Net income growth+18.9%-3.1%+326.7%-69.8%-37.1%-
Revenue CAGR (3Y)+15.3%+3.3%+4.2%---
EBITDA CAGR (3Y)+48.9%+15.5%-4.1%---
Profitability & leverage
Net income margin+12.6%+12.9%+14.2%+4.3%+11.3%+19.6%
Return on capital employed+12.2%+14.0%+15.4%+6.3%+17.5%+32.7%
Return on net worth+11.2%+12.7%+15.2%+4.0%+13.8%+27.1%
Debt / equity0.480.520.350.230.100.18
Long-term debt / equity0.170.290.230.090.000.00
Interest cover14.8210.605.9719.852.973.94
Efficiency & per share
Fixed asset turnover0.841.151.311.321.771.88
Inventory turnover3.492.522.472.312.892.77
Debtors turnover4.664.996.034.445.215.65
EPS (₹)17.5217.7091.4921.4870.89112.73
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)183.27149.03653.85568.34547.46475.97
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue220211213226202204
Revenue growth (YoY)+9.0%+3.2%----
Other income20.2319.5518.6814.5312.0511.47
Total expenses160152217165141142
EBITDA59.9859.24(3.87)60.5160.5162.34
EBITDA margin+27.3%+28.1%-1.8%+26.8%+30.0%+30.5%
Depreciation10.0310.1511.319.389.389.30
Interest4.975.626.455.906.345.11
Profit before tax65.2163.02(2.95)59.7656.8459.40
Tax16.6716.0112.7315.3414.2614.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue845757674564634623
Revenue growth+11.7%+12.3%+19.5%-11.1%+1.8%-
Other income56.7332.0019.7612.375.659.01
Total expenses666538531548529420
Employee cost0.0011910292.5581.7472.77
EBITDA18021914315.52105202
EBITDA margin+21.2%+28.9%+21.2%+2.8%+16.6%+32.5%
Depreciation39.3738.3637.2627.6225.1122.18
Interest23.8016.657.548.053.076.52
Profit before tax173196118(7.78)82.77183
Tax57.2350.2028.9514.8821.0547.11
Net profit15614688.9356.9961.72136
Net profit margin+18.5%+19.3%+13.2%+10.1%+9.7%+21.8%
EPS (₹)20.03133.3581.33(20.72)56.45123.96
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital-10.9410.9410.9410.9410.94
Reserves & surplus-900750662684622
Shareholders' funds (net worth)-911761673695633
Secured loans-29351.7210763.5947.42
Unsecured loans-0.000.000.000.000.00
Total debt-29351.7210763.5947.42
Total liabilities-1,219825787765687
Assets
Gross block-545514418392349
Net block-317324266266248
Capital work in progress-59.0519.3673.9022.6226.73
Investments-44.2042.2565.60130123
Inventories-254333242245225
Sundry debtors-176125112144119
Cash & bank balances-22.596.272.836.3241.14
Loans & advances-26.6333.9829.7620.2426.94
Total current assets-479498387416412
Total current liabilities-108248108109136
Net working capital-371250278306276
Total assets-1,219825787765687
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash-6.202.535.150.741.07
Net cash from operating activities-83.2914793.3523.62158
Net cash from investing activities-(292)(80.80)(132)(33.94)(78.99)
Net cash from financing activities-225(62.98)36.5314.73(79.04)
Net change in cash-16.313.67(2.62)4.41(0.33)
Closing cash-22.596.272.836.3241.14
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+11.7%+12.3%+19.5%-11.1%+1.8%-
EBITDA growth-18.0%+53.2%+820.9%-85.3%-48.0%-
PBT growth-11.7%+66.3%+9998.0%--54.7%+9997.0%
Net income growth+6.9%+64.0%+56.0%-7.7%-54.5%-
Revenue CAGR (3Y)+14.5%+6.1%+2.7%---
EBITDA CAGR (3Y)+126.2%+27.7%-10.9%---
Profitability & leverage
Net income margin+13.7%+19.3%+13.2%-4.0%+9.7%+21.8%
Return on capital employed-+20.8%+15.6%+8.4%+11.8%+28.9%
Return on net worth-+17.4%+12.4%+8.3%+9.3%+24.0%
Debt / equity-0.210.110.120.080.15
Long-term debt / equity-0.030.000.000.000.00
Interest cover16.989.227.14-66.533.833.62
Efficiency & per share
Fixed asset turnover-1.431.451.391.711.89
Inventory turnover-2.582.352.312.692.73
Debtors turnover-5.025.674.404.835.52
EPS (₹)20.03133.3581.33(20.72)56.45123.96
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)0.00832.83695.99615.23635.68579.15

Timeline of Symbiotec

6 dated milestones of Symbiotec across 24 years, from founding to its latest funding, stage changes and deals.

  1. Founded Symbiotec is founded.
  2. Funding First funding round of $3.7M.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Series C, of $48.0M.
  5. Exit Acquired by Rosewood Private Intvestments.
  6. IPO Lists on the stock exchange (IPO).

Competitors of Symbiotec

Symbiotec has 3 listed competitors in our database, 1 of them funded. They include Laurus Labs, Jubilant Pharma and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Laurus Labs
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
Jubilant Pharma
jubilantpharma.com1978Noida, India
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
SeQuent
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed competitors of Symbiotec

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Symbiotec

Websites that share an audience with Symbiotec (symbiotec.in).

Similar websites

Websites whose visitors overlap most with Symbiotec. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
montagelabs.com
montagelabs.com
100%
#2,575,865–
systole.co.in
systole.co.in
90%
#2,140,628–

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Symbiotec (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Symbiotec

Symbiotec Pharmalab Shares Make Muted Market Debut; Bounce Back Later – Outlook Business
Outlook Business • 2 months ago
Symbiotec Pharmalab IPO Day 1: Issue subscribed at 0.70x by mid-afternoon - The HinduBusinessLine
Thehindubusinessline • 2 months ago
Subscribe for Symbiotec Pharmalab Ltd IPO; Geojit Financial Services
Moneycontrol • 2 months ago
Symbiotec Pharmalab raises ₹526 cr from anchor investors; IPO opens Aug 24 | Company News - Business Standard
Business Standard • 2 months ago
Are InvAscent, MO Alts beating the benchmark in partial exit from pharma company?
VCCircle • 2 months ago
Grapevine: Symbiotec Pharmalab, Adani Energy, Megha Engineering, Suntory in news
VCCircle • 1 year ago
PE firm InvAscent keen to list five portfolio companies
Livemint • 2 years ago
Actis Invests $48 Million In Indian Pharma Company
Act • 3 years ago
Mid-market PE consortium in talks to buy Actis' stake in Symbiotec
Vccircle • 8 years ago
Global Prednisolone Acetate Market Overview 2018- Sanofi, Symbiotec Pharma, Xianju Pharma, Wuhan DKY Technology
Truthweek • 8 years ago
Premium access

Complete news archive for Symbiotec

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Symbiotec

Symbiotec was founded in 2002 and raised its 1st funding round 5 years after it was founded.

Symbiotec is headquartered in Indore, India. It is registered at Indore, Madhya Pradesh, India.

Symbiotec is a funded company, having raised a total of $61.01M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3.72M, raised on Aug 2007.

Symbiotec has 1,822 employees.

The primary company behind Symbiotec, Symbiotec Pharmalab Limited, reported revenue of ₹872 Cr for FY 2026, up 16% year on year.

Symbiotec was established in 2002 in Indore, India, as a manufacturer in the pharmaceutical sector. Non-sterile APIs and intermediates derived from steroid hormones are produced, targeting therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, pediatrics, anti-infectives, and dermatology. Regulatory-compliant solutions are offered, alongside operations in research and quality control laboratories.

Symbiotec's top competitors include Laurus Labs, SeQuent and Jubilant Pharma.

Symbiotec offers Cortico-Steroid API, Steroid-Hormone API, and Intermediates.

Yes, Symbiotec is publicly traded on NSE under the ticker symbol SYMBIOTEC.

Symbiotec has 9 investors. Key investors include Actis, Franklin Templeton, British International Investment, R S Shapeti, and Rakesh Jhunjhunwala.

The valuation of Symbiotec is $32.19M as of Mar 2013.

Symbiotec is associated with 4 legal entities: Symbiotec Pharmalab Limited, Tdv Commercials Llp, Spl Lifescience India Private Limited and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available